Biotech Boosts Funding to Target Genes Behind Neurological Diseases
Aerska, a biotech startup, has recently secured $39 million in funding to advance its innovative treatments aimed at targeting genes responsible for neurological diseases. This investment comes just four months after the company completed its initial funding round, marking a rare occurrence of consecutive fundraising success in the biotech sector.
About Aerska
Founded by entrepreneur Jack O’Meara and former Alnylam Pharmaceuticals executive Stuart Milstein, Aerska operates from its offices in Dublin and London. The company’s mission is to tackle brain diseases by utilizing a novel approach to drug delivery.
Innovative Technology
Aerska’s technology focuses on utilizing “brain shuttles” designed to transport larger drug molecules through the blood-brain barrier, a challenge that often hinders treatment efficacy. This barrier typically prevents many therapeutic agents from reaching their target in the brain.
- The technology uses small packages of small interfering RNAs (siRNAs).
- siRNAs can regulate gene expression and interfere with damaging protein production.
- The delivery mechanism exploits the brain’s high demand for iron, disguising the drugs as iron-rich antibodies.
O’Meara humorously likened the delivery system to coating drugs in Guinness, referencing the popular Irish stout’s perceived iron content.
Implications for Neurological Diseases
The advancements achieved by Aerska could play a critical role in treating various brain disorders caused by genetic factors. The startup’s innovative approach positions it as a frontrunner in the biotech industry, with the potential to change treatment paradigms for neurological conditions.
With the recent funding boost, Aerska is poised to accelerate its development plans and further explore the promise of gene-targeted therapies in neuroscience.
